1082
1082
995
995
1044
1044
891
891
852
852
892
892
777
777
769
769
754
754
781
781
2018
2009
Company (35.2K)University (773)Hospital (400)Research Institution (245)Foundation (22)Investor (16)Other (7)
1 - 10 of 35,281
Sort by
Patent
Publication NumberUS 10597392Filing StatusIssued PatentAvailabilityUnknownFiling Date2018-11-30Publication Date2020-03-24
The present invention provides compounds of formula I: which are useful as modulators of GPR6, pharmaceutical compositions thereof, methods for treatment of conditions associated with GPR6, processes for making the compounds and intermediates thereof.
Patent
Publication NumberUS 20200085821Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2019-04-23Publication Date2020-03-19
Disclosed are chemical entities which are compounds of formula (I): or pharmaceutically acceptable salts thereof; wherein Y, Ra, Ra′, Rb, Rc, X1, X2, X3, Rd, Z1, and Z2 have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosu…
Patent
Publication NumberUS 20200087401Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2018-05-26Publication Date2020-03-19
The invention provides methods for the treatment of chronic pouchitis comprising administering an anti-α4β7 antibody, e.g., vedolizumab, to a human subject in need thereof.
Patent
Publication NumberUS 10590390Filing StatusIssued PatentAvailabilityUnknownFiling Date2015-08-03Publication Date2020-03-17
The present invention relates to a method for preparing highly pure pancreatic progenitor cells by using pluripotent stem cells such as ES cells or iPS cells as a source, inducing their differentiation into pancreatic progenitor cells, and culturing and proliferating the pancreatic progenitor cells. Specifically, the present invention relates to a method for proliferation of pancreatic progenitor cells, comprising the step of culturing the pancreatic progenitor cells in a medium containing (i…
Patent
Publication NumberUS 10584097Filing StatusIssued PatentAvailabilityUnknownFiling Date2019-09-20Publication Date2020-03-10
The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
Patent
Publication NumberUS 20200069751Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2019-03-07Publication Date2020-03-05
The invention relates to a unit dose of a dengue vaccine composition and methods and uses for preventing dengue disease and methods for stimulating an immune response to all four dengue virus serotypes in a subject or subject population. The unit dose of a dengue vaccine composition includes constructs of each dengue serotype, such as TDV-1, TDV-2, TDV-3 and TDV-4, at various concentrations in order to improve protection from dengue infection.
Patent
Publication NumberUS 10577382Filing StatusIssued PatentAvailabilityUnknownFiling Date2017-04-27Publication Date2020-03-03
Provided is a compound represented by the following formula, or a salt thereof: [wherein each symbol is as defined herein].
Clinical Trial
Clinical Trial IDNCT04151420Start Date2020-03-01Completion Date2022-04-01Study TypeObservationalStatusNot yet recruiting
Inflammatory bowel disease (IBD) is a chronic relapsing immune mediated inflammatory disease (IMID) of the gastrointestinal. Like all IMIDs (e.g. rheumatoid arthritis, psoriasis) a complex interaction between a genetically altered immune response, the gut microbiota and environmental factors is causing the disease. Systemic suppression of the immune response with corticosteroids, immunomodulatory, biologicals and combination therapies increases the risk of opportunistic infections in IBD pati…
Clinical Trial
Clinical Trial IDNCT03880123Start Date2020-03-01Completion Date2020-08-01PhasePhase 1Study TypeInterventionalStatusNot yet recruiting
The main purpose of this study is to establish a safe and tolerable dose combination (the "maximum tolerated dose") of selinexor and ixazomib when used together for the treatment of patients with certain types of advanced sarcoma. The study will enroll patients with advanced dedifferentiated liposarcoma, malignant peripheral nerve sheath tumor, alveolar soft part sarcoma and Ewing sarcoma. Future studies to further evaluate the safety and anti-cancer efficacy of this treatment for sarcoma wil…
Patent
Publication NumberUS 20200061151Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2019-09-05Publication Date2020-02-27
Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclose…
We found 35,281 documents that match your Search
Research Grants: 57
Publications: 107
Patents: 32,969
Clinical Trials: 2,148

Wellspring Search is the world's most comprehensive collection of enriched content about emerging and licensable technology innovations.


Already a member? Sign in